Received orphan drug designation from the U.S. FDA for targeted anticancer drug, ivaltinostat, to treat acute myeloid leukemia (AML)

Applied for regulatory approval of Acelex, next-gen anti-inflammatory drug, in Brazil

Reported completion of Phase 1 SAD study for CG-750

Completed Phase 1 study for polmacoxib + pregabalin FDC

Selected by Korea's Financial Services Commission as one of the top 1000 innovative firms to support

Received designation for expedited approval of ivaltinostat by Korea's Ministry of Food and Drug Safety

Received orphan drug designation from the U.S. FDA for ivaltinostat to treat hepatocellular carcinoma

Signed tech transfer agreement with Machaon Therapeutics for the right to develop ivaltinostat for fibrotic diseases

Established subsidiary, Machaon Therapuetics, to focus on developing therapeutics for fibrosis

Completed EU Phase 1 study of CG-549 (novel antibiotic with improved formulation) to treat MRSA infections

Granted a patent for a new drug candidate (ivaltinostat) for acute myelogenous leukemia in Australia

Signed a license-in contract for the PD-1 inhibitor, camrelizumab, with China's Jiangsu Hengrui Medicine Co., Ltd.

Completed Phase 2 study of ivaltinostat for treatment of pancreatic cancer

Granted a U.S. patent for a new drug candidate (ivaltinostat) for acute myeloid leukemia

Granted a patent for polmacoxib for arthritis / inflammatory diseases in Australia

Established Crystal Bioscience, a new technology investment company

Granted a Korean patent for transdermal formulation of polmacoxib

Acquired license for manufacturing and sales of Acelex tablets by Korea's Ministry of Food and Drug Safety

Received orphan drug designation from the U.S. FDA for ivaltinostat to treat pancreatic cancer

Received the top award at the "ITS 2019 Innovative Technology Show’ from the Ministry of Small Medium Enterprise and Startups

Acquired EMA IND approval for Phase 1 study of CG-549 to treat MRSA infections

Granted a Korean patent for a new drug candidate (ivaltinostat) for acute myelogenous leukemia

Granted a U.S. patent for polmacoxib for arthritis / inflammatory diseases

Completed Korean Phase 1 study for polmacoxib + tramadol FDC

Acquired IND approval for Phase 1 study for polmacoxib + pregabalin FDC

Signed export agreement of polmacoxib with PharmArtis for expansion of commercialization into the Eurasian Economic Union (EAEU)

Acquired FDA IND approval for the Phase 1 study of CG-806 for acute myelogenous leukemia

Granted a patent for CG-806 for acute myelogenous leukemia in Turkey

Granted a patent for CG-806 for acute myelogenous leukemia in Russia

Awarded as ‘Excellent Corporation R&D Center’ by the Ministry of Science and Information Communication Technology

Awarded as ’World Class Product of Korea’ (Acelex) by the Ministry of Trade, Industry and Energy

Signed export agreement of polmacoxib with PharmArtis for commercialization in Russia

Awarded as ‘Korea"s Innovative Pharmaceutical Company’ by President of Korea Health Industry Development Institute

Filed for patent for ivaltinostat - oral formulation

Received "Osong New Drug & Medical Expert" Grand Award

Signed export agreement of polmacoxib with APSEN for commercialization in Brazil

Granted a patent for CG-806 for acute myelogenous leukemia in Europe

Granted a patent for polmacoxib for arthritis and inflammatory diseases in Europe

Signed agreement with Aptose Biosciences (U.S.) for Aptose to acquire licensing rights to export CG-806 into China to treat hematological malignancies

Designated ivaltinostat as an "Developmental Orphan Drug" by Korea"s Ministry of Food and Drug Safety for pancreatic cancer

Renewed the designation as an Innovative Pharmaceutical Company by the Korean government

Acquired IND approval for Phase 1 study for polmacoxib + tramadol FDC from Ministry of Food and Drug Safety

Signed agreement with Daewoong Pharmaceutical for commercialization of Acelex in Korea

Received trademark rights of next-gen arthritis and anti-inflammatory drug ‘Acelex’ in 35 countries

Granted a patent for CG-806 for acute myelogenous leukemia in China

Granted a patent for polmacoxib for arthritis and inflammatory diseases in Japan

Awarded “President’s Award” from “2017 Korea Technology Convention” by Ministry of Trade, Industry and Energy

Granted a patent for CG-806 for acute myelogenous leukemia in U.S.

Granted a Korean patent for polmacoxib + tramadol FDC to treat moderate to severe chronic pain

Received the 2016 Prime Minister's iR52 Jang Young-shil Award from KOITA, MBN, Ministry of Science and ICT

Re-nominated as a “K-Brain Power” company by Korea's Ministry of Trade, Industry and Energy

Licensed out CG-806 to Aptose Biosciences, Inc. (U.S.)

Received “Korea New Drug Grand Award” by Korea Drug Research Association

Signed export agreement of Acelex with TR Pharm for commercialization in MENA and Turkey

Received ‘Korea Innovative Pharmaceutical Company’ award from Korea"s Ministry of Health and Welfare

Acquired BTO Biopharmaceuticals (now known as CrystalLifeSciences Co., Ltd.)

Signed agreement with Dong-A ST Co., Ltd. for sales and marketing of Acelex

Received IND approval for Phase 1/2 clinical study for ivaltinostat to treat myelodysplastic syndrome (MDS)

Received NDA approval of Acelex (next-gen arthritis / anti-inflammatory drug) becoming the 22nd new drug approved in Korea and 1st from a Korean bioventure

Designated ivaltinostat as an "Developmental Orphan Drug" by Korea"s Ministry of Food and Drug Safety for MDS

Received IND approval for Phase 1/2 clinical study for ivaltinostat to treat pancreatic ductal adenocarcinoma

Acquired controlling stake of Hwail Pharma Co., Ltd.

Completed Phase 1 clinical study of ivaltinostat

Reported U.S. Phase 2a clinical study results for CG-549 (antibiotic candidate) to treat MRSA

Received IND approval for Phase 3 clinical study for Acelex

Designated as "Korea Innovative Pharmaceutical Company" by the Ministry of Health and Welfare

Completed Phase 2b clinical study of Acelex

Received IND approval from the FDA for Phase 2a clinical study for CG-549 to treat MRSA

Received investment from the "Global Biomedical New Growth Power Investment Fund" by the Seoul metropolitan government

Awarded a grant from Korea's OncoVenture fund for the Global Oncology Drug Development program

Relocated HQ to Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeongi-do, Republic of Korea

Acquired NexioLab

Received IND approval from MFDS for Phase 1 MAD clinical study for ivaltinostat

Completed Phase 1 MAD clinical study in Europe for CG-549 to treat MRSA

Received IND approval from MFDS for Phase 2b clinical study for Acelex